Faculty Opinions recommendation of Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein ◽

Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar

Molecular Pharmaceutics ◽

10.1021/mp3003144 ◽

2012 ◽

Vol 9 (11) ◽

pp. 3236-3245 ◽

Cited By ~ 82

Author(s):

Selvi Durmus ◽

Rolf W. Sparidans ◽

Els Wagenaar ◽

Jos H. Beijnen ◽

Alfred H. Schinkel

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein ◽

Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models

Journal of Pharmaceutical Sciences ◽

10.1016/j.xphs.2018.03.018 ◽

2018 ◽

Vol 107 (8) ◽

pp. 2225-2235 ◽

Cited By ~ 10

Author(s):

Bo Feng ◽

Angela C. Doran ◽

Li Di ◽

Mark A. West ◽

Sarah M. Osgood ◽

...

Keyword(s):

Breast Cancer ◽

Animal Models ◽

Human Brain ◽

Cancer Resistance ◽

Brain Penetration ◽

Protein Substrates ◽

P Glycoprotein ◽

Resistance Protein

P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-1335 ◽

2007 ◽

Vol 13 (21) ◽

pp. 6440-6449 ◽

Cited By ~ 172

Author(s):

Nienke A. de Vries ◽

Jin Zhao ◽

Emily Kroon ◽

Tessa Buckle ◽

Jos H. Beijnen ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Working Together ◽

Resistance Protein ◽

The Brain

Evaluation of Limiting Brain Penetration Related to P-glycoprotein and Breast Cancer Resistance Protein Using [11C]GF120918 by PET in Mice

Molecular Imaging and Biology ◽

10.1007/s11307-010-0313-1 ◽

2010 ◽

Vol 13 (1) ◽

pp. 152-160 ◽

Cited By ~ 34

Author(s):

Kazunori Kawamura ◽

Tomoteru Yamasaki ◽

Fujiko Konno ◽

Joji Yui ◽

Akiko Hatori ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein

Faculty Opinions recommendation of The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1157296.617432 ◽

2009 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Imatinib Mesylate ◽

Propanoic Acid ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein ◽

The Brain

Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography

Nuclear Medicine and Biology ◽

10.1016/j.nucmedbio.2010.12.012 ◽

2011 ◽

Vol 38 (5) ◽

pp. 707-714 ◽

Cited By ~ 21

Author(s):

Tomoteru Yamasaki ◽

Masayuki Fujinaga ◽

Kazunori Kawamura ◽

Akiko Hatori ◽

Joji Yui ◽

...

Keyword(s):

Breast Cancer ◽

Positron Emission Tomography ◽

Small Animal ◽

Emission Tomography ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Positron Emission ◽

Resistance Protein

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

International Journal of Cancer ◽

10.1002/ijc.28475 ◽

2013 ◽

Vol 134 (6) ◽

pp. 1484-1494 ◽

Cited By ~ 90

Author(s):

Seng Chuan Tang ◽

Luan N. Nguyen ◽

Rolf W. Sparidans ◽

Els Wagenaar ◽

Jos H. Beijnen ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Alk Inhibitor ◽

P Glycoprotein ◽

Resistance Protein ◽

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability

Pharmacological Research ◽

10.1016/j.phrs.2018.09.020 ◽

2018 ◽

Vol 137 ◽

pp. 47-55 ◽

Cited By ~ 8

Author(s):

Wenlong Li ◽

Rolf W. Sparidans ◽

Yaogeng Wang ◽

Maria C. Lebre ◽

Jos H. Beijnen ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

P Glycoprotein ◽

Resistance Protein ◽

Faculty Opinions recommendation of Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727409671.793569213 ◽

2020 ◽

Author(s):

Michael Gottesman

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Glycoprotein P ◽

P Glycoprotein ◽

Resistance Protein ◽

Faculty Opinions recommendation of P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734076177.793556597 ◽

2019 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

P Glycoprotein ◽

Resistance Protein ◽